263 related articles for article (PubMed ID: 23764929)
1. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.
Arihara F; Mizukoshi E; Kitahara M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
Cancer Immunol Immunother; 2013 Aug; 62(8):1421-30. PubMed ID: 23764929
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
[TBL] [Abstract][Full Text] [Related]
3. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.
Wang D; An G; Xie S; Yao Y; Feng G
Tumour Biol; 2016 Aug; 37(8):10427-33. PubMed ID: 26846107
[TBL] [Abstract][Full Text] [Related]
4. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Hoechst B; Ormandy LA; Ballmaier M; Lehner F; Krüger C; Manns MP; Greten TF; Korangy F
Gastroenterology; 2008 Jul; 135(1):234-43. PubMed ID: 18485901
[TBL] [Abstract][Full Text] [Related]
5. Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
Wang Z; Zhang L; Wang H; Xiong S; Li Y; Tao Q; Xiao W; Qin H; Wang Y; Zhai Z
Cancer Immunol Immunother; 2015 Mar; 64(3):389-99. PubMed ID: 25548095
[TBL] [Abstract][Full Text] [Related]
6. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
Tian T; Gu X; Zhang B; Liu Y; Yuan C; Shao L; Guo Y; Fan K
Cancer Biomark; 2015; 15(4):425-32. PubMed ID: 25792471
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Terashima T; Kitahara M; Nakagawa H; Iida N; Fushimi K; Kaneko S
Cancer Immunol Immunother; 2016 Jun; 65(6):715-25. PubMed ID: 27083166
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.
Boral B; Ballı HT; Sözütok S; Pehlivan UA; Aikimbaev K
Scand J Immunol; 2022 Mar; 95(3):e13132. PubMed ID: 34936119
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
Jordan KR; Amaria RN; Ramirez O; Callihan EB; Gao D; Borakove M; Manthey E; Borges VF; McCarter MD
Cancer Immunol Immunother; 2013 Nov; 62(11):1711-22. PubMed ID: 24072401
[TBL] [Abstract][Full Text] [Related]
10. IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.
Chen MF; Kuan FC; Yen TC; Lu MS; Lin PY; Chung YH; Chen WC; Lee KD
Oncotarget; 2014 Sep; 5(18):8716-28. PubMed ID: 25238263
[TBL] [Abstract][Full Text] [Related]
11. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
12. Circulating CD14
Gao XH; Tian L; Wu J; Ma XL; Zhang CY; Zhou Y; Sun YF; Hu B; Qiu SJ; Zhou J; Fan J; Guo W; Yang XR
Hepatol Res; 2017 Sep; 47(10):1061-1071. PubMed ID: 27764536
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
14. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
Höchst B; Schildberg FA; Sauerborn P; Gäbel YA; Gevensleben H; Goltz D; Heukamp LC; Türler A; Ballmaier M; Gieseke F; Müller I; Kalff J; Kurts C; Knolle PA; Diehl L
J Hepatol; 2013 Sep; 59(3):528-35. PubMed ID: 23665041
[TBL] [Abstract][Full Text] [Related]
15. Elevated frequencies of CD14
Xue G; Jiang M; Zhao R; Le A; Li J
Aging (Albany NY); 2021 Feb; 13(5):6236-6246. PubMed ID: 33640878
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation.
Chen PH; Kao WY; Chiou YY; Hung HH; Su CW; Chou YH; Huo TI; Huang YH; Wu WC; Chao Y; Lin HC; Wu JC
Ann Hepatol; 2013; 12(2):263-73. PubMed ID: 23396738
[TBL] [Abstract][Full Text] [Related]
17. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.
Jitschin R; Braun M; Büttner M; Dettmer-Wilde K; Bricks J; Berger J; Eckart MJ; Krause SW; Oefner PJ; Le Blanc K; Mackensen A; Mougiakakos D
Blood; 2014 Jul; 124(5):750-60. PubMed ID: 24850760
[TBL] [Abstract][Full Text] [Related]
18. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
Huang A; Zhang B; Wang B; Zhang F; Fan KX; Guo YJ
Cancer Immunol Immunother; 2013 Sep; 62(9):1439-51. PubMed ID: 23760662
[TBL] [Abstract][Full Text] [Related]
19. Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.
Tsuchiya K; Komuta M; Yasui Y; Tamaki N; Hosokawa T; Ueda K; Kuzuya T; Itakura J; Nakanishi H; Takahashi Y; Kurosaki M; Asahina Y; Enomoto N; Sakamoto M; Izumi N
Oncology; 2011; 80(3-4):278-88. PubMed ID: 21734420
[TBL] [Abstract][Full Text] [Related]
20. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
